Finance & Capital Management

There's potential for “a bit of revenue” from a revamped pot regime, but the federal government isn't looking for a financial windfall.

Martin Shkreli became the new face of corporate greed when he jacked up the price of a lifesaving drug fiftyfold.

Province originally decided not to pay for expensive drug that could help boy suffering from rare genetic disorder.

Dip due to intensifying competition for drug information services, association's CEO explains.